Eugenol Elicits Prolongevity by Increasing Resistance to Oxidative Stress
in <i>C. elegans</i>

Parween, Nikhat; Jabeen, Amber; Prasad, Birendra

doi:10.2174/1871527320666211008150347

Cited by 4 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Parween et al showed that eugenol significantly improved healthy ageing and slowed neurodegeneration in a CL4176 worm (Caenorhabditis elegans) Alzheimer’s model by enhancing oxidative stress resistance and slowing paralysis [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

The Effect of Combined Treatment of Psilocybin and Eugenol on Lipopolysaccharide-Induced Brain Inflammation in Mice

et al. 2023

View full text Add to dashboard Cite

Inflammation is an organism’s biological defense mechanism. Acute and chronic inflammation of the body triggers the production of pro- and anti-inflammatory pathways that can affect the content of cytokines in the brain and thus cause brain inflammation. Disorders such as depression and posttraumatic stress disorder (PTSD) are often associated with elevated inflammation. Recently, positive and promising clinical results of psilocybin for the treatment of depression and PTSD were reported. Thus, we decided to test whether psilocybin alone or in combination with eugenol, an anti-inflammatory and antioxidant agent, would prevent the increase in or decrease the content of cytokines in the brain of C57BL/6J mice injected with lipopolysaccharides (LPS). Two experiments were performed, one with pre-treatment of mice through gavage with psilocybin (0.88 mg/kg), eugenol (17.6 mg/kg), or combinations of psilocybin and eugenol (1:10, 1:20, or 1:50), followed by intraperitoneal injection of LPS, and the second, post-treatment, with initial injection with LPS, followed by treatment with psilocybin, eugenol, or their combination. Brain tissues were collected, and cytokines were analyzed by qRT-PCR, Western blot, and ELISA. Data were analyzed with a one-way ANOVA followed by Tukey’s post hoc test or with multiple unpaired t-tests. LPS upregulated mRNA expression of COX-2, TNF-α, IL-1β, and IL-6. All pre-treatments decreased the expression of COX-2 and TNF-α, with psilocybin alone and in 1:50 combination, with eugenol being the most effective. In the post-treatment, all combinations of psilocybin and eugenol were effective in reducing inflammation, with the 1:50 ratio displaying the most prominent results in reducing the mRNA content of tested cytokines. Western blot analysis confirmed the effect on COX-2 and IL-1β proteins. Finally, the ELISA showed that post-treatment with psilocybin + eugenol (1:50) demonstrated the best results, decreasing the expression of multiple markers including IL-6 and IL-8. This demonstrates the anti-inflammatory effects of a combination of psilocybin and eugenol in the brain of animals with systemically induced inflammation.

show abstract

Section: Introductionmentioning

confidence: 99%

The Effect of Combined Treatment of Psilocybin and Eugenol on Lipopolysaccharide-Induced Brain Inflammation in Mice

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Eugenol has been reported in in vitro and in vivo models, enabling a range of pharmacological applications. Among these, it can be mentioned: anti‐inflammatory, 29 analgesic, 30 anaesthetic, 31,32 antioxidant 9,10 and neuroprotective activities 6,7,11 . The antioxidant potential of Eugenol is based on hydroxyl radicals scavenging, and by reduced glutathione (GSH), reducing the formation of reactive oxygen species (ROS) 7,27,33,34 .…”

Section: Phenolic Compoundsmentioning

confidence: 99%

Exploring promising minor natural phenolic compounds in neuroprotection‐related preclinical models

Moreira Vasconcelos,

Neugebauer,

Basto Souza

2024

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, are characterised by the progressive loss of specific neuronal cell populations due to multifactorial factors, including neurochemical and immunological disturbances. Consequently, patients can develop cognitive, motor and behavioural dysfunctions, which lead to impairments in their quality of life. Over the years, studies have reported on the neuroprotective properties inherent in phenolic compounds. Therefore, this review highlights the most recent scientific findings regarding phenolic compounds as promising neuroprotective molecules against neurodegenerative diseases.

show abstract

“…Some foods or other items used in gastronomy were also evaluated. These included maple syrup [ 111 ], fruits such as strawberry (Fragaria × ananassa ) [ 112 ], pomegranate ( Punica granatum L.) [ 113 , 114 ], guarana ( Paullinia cupana Kunth) [ 115 ] and cranberry ( Vaccinium ) [ 116 ], and spices such as holy basil ( Ocimum sanctum ) [ 117 ] and turmeric ( Curcuma longa L.) [ 114 ]. Other tested natural products were the extracts of flowers such as red rose ( Rosa x hybrida ) [ 118 ], roselle ( Hibiscus sabdariffa L.) [ 119 ], horned violet ( Viola cornuta ), and pansy ( Viola x wittrockiana ) [ 120 ]; essential oils from Kushui rose ( Rosa setate × Rosa rugosa ) [ 121 ]; Japanese zelkova ( Zelkova serrata (Thunb.)…”

Section: Effects Of Natural Products In Caenorhabditis Eleg...mentioning

confidence: 99%

Natural Bioactive Products and Alzheimer’s Disease Pathology: Lessons from Caenorhabditis elegans Transgenic Models

Navarro-Hortal¹,

Romero-Márquez²,

Osta³

et al. 2022

Diseases

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is an age-dependent, progressive disorder affecting millions of people. Currently, the therapeutics for AD only treat the symptoms. Although they have been used to discover new products of interest for this disease, mammalian models used to investigate the molecular determinants of this disease are often prohibitively expensive, time-consuming and very complex. On the other hand, cell cultures lack the organism complexity involved in AD. Given the highly conserved neurological pathways between mammals and invertebrates, Caenorhabditis elegans has emerged as a powerful tool for the investigation of the pathophysiology of human AD. Numerous models of both Tau- and Aβ-induced toxicity, the two prime components observed to correlate with AD pathology and the ease of performing RNA interference for any gene in the C. elegans genome, allow for the identification of multiple therapeutic targets. The effects of many natural products in main AD hallmarks using these models suggest promising health-promoting effects. However, the way in which they exert such effects is not entirely clear. One of the reasons is that various possible therapeutic targets have not been evaluated in many studies. The present review aims to explore shared therapeutical targets and the potential of each of them for AD treatment or prevention.

show abstract

Eugenol Elicits Prolongevity by Increasing Resistance to Oxidative Stress in C. elegans

Cited by 4 publications

References 39 publications

The Effect of Combined Treatment of Psilocybin and Eugenol on Lipopolysaccharide-Induced Brain Inflammation in Mice

The Effect of Combined Treatment of Psilocybin and Eugenol on Lipopolysaccharide-Induced Brain Inflammation in Mice

Exploring promising minor natural phenolic compounds in neuroprotection‐related preclinical models

Natural Bioactive Products and Alzheimer’s Disease Pathology: Lessons from Caenorhabditis elegans Transgenic Models

Contact Info

Product

Resources

About